|8/8/2022||U.S. FDA approves additional indication of darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)|
|6/28/2022||Orion publishes Half-Year Financial Report for January–June 2022 on Friday 15 July 2022|
|5/9/2022||The negotiations under the Act on Co-operation within Undertakings concerning Orion’s R&D have been completed – future focus on pain and oncology|
|5/6/2022||Orion enters into exclusive agreement with Jemincare for novel non-opioid drug candidate for the treatment of pain|
|7/15/2022||Orion Group Half-Year Financial Report 1–6/2022|
|7/15/2022||Orion Corporation's financial reporting and Annual General Meeting in 2023|
|7/13/2022||Orion upgrades full-year outlook for 2022 following the USD 290 million upfront payment regarding ODM-208 agreement|
|7/13/2022||Orion and MSD announce global collaboration for the development and commercialisation of ODM-208, an investigational steroid synthesis inhibitor for the treatment of metastatic castration-resistant prostate cancer|
The Annual General Meeting of Orion Corporation was held on Wednesday 23 March 2022. The decisions and related material are available here.
Orion published Half-Year Financial Report 1-6/2022 on Friday, 15 July 2022. The report, related presentation material and a link to a live webcast are available here.
The product and service portfolio of Orion includes a variety of human pharmaceuticals, veterinary drugs, APIs and contract manufacturing.
Orion is the largest employer in the Finnish pharmaceutical industry. It is considered to be a good and reliable employer, which is also indicated by its lower-than-average employee turnover.